Literature DB >> 16304201

Human immunodeficiency virus type 1 latency model for high-throughput screening.

Sofiya Micheva-Viteva1, Annmarie L Pacchia, Yacov Ron, Stuart W Peltz, Joseph P Dougherty.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304201      PMCID： PMC1315948          DOI： 10.1128/AAC.49.12.5185-5188.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

4.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Influence of cell cycle on HIV-1 expression differs among various models of chronic infection.

Authors:  B D Roberts; G Fang; S T Butera
Journal:  Arch Virol       Date:  1997       Impact factor: 2.574

6.  HIV-1 latency due to the site of proviral integration.

Authors:  B J Winslow; R J Pomerantz; O Bagasra; D Trono
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

7.  Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.

Authors:  M K Lewinski; D Bisgrove; P Shinn; H Chen; C Hoffmann; S Hannenhalli; E Verdin; C C Berry; J R Ecker; F D Bushman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.

Authors:  A Jordan; P Defechereux; E Verdin
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

9.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.

Authors:  D F Purcell; M A Martin
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103
View more
  16 in total

1.  High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.

Authors:  Sofiya Micheva-Viteva; Yoshifumi Kobayashi; Leonard C Edelstein; Annmarie L Pacchia; Hui-Ling Rose Lee; Jason D Graci; Jamie Breslin; Bradley D Phelan; Leia K Miller; Joseph M Colacino; Zhengxian Gu; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

2.  Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency.

Authors:  Benni Vargas; Nicholas S Giacobbi; Anwesha Sanyal; Narasimhan J Venkatachari; Feng Han; Phalguni Gupta; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.

Authors:  Vicente Planelles; Frank Wolschendorf; Olaf Kutsch
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

4.  Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.

Authors:  Oyebisi Jegede; Ana Khodyakova; Mikhail Chernov; Jan Weber; Luis Menéndez-Arias; Andrei Gudkov; Miguel E Quiñones-Mateu
Journal:  Antiviral Res       Date:  2011-05-12       Impact factor: 5.970

Review 5.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

6.  Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

Authors:  Leonard C Edelstein; Sophia Micheva-Viteva; Bradley D Phelan; Joseph P Dougherty
Journal:  AIDS Res Hum Retroviruses       Date:  2009-09       Impact factor: 2.205

Review 7.  Facilitating compound progression of antiretroviral agents via modeling and simulation.

Authors:  Jeffrey S Barrett
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-17       Impact factor: 4.147

Review 8.  Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Mark A Wainberg
Journal:  Retrovirology       Date:  2013-02-01       Impact factor: 4.602

9.  Digoxin suppresses HIV-1 replication by altering viral RNA processing.

Authors:  Raymond W Wong; Ahalya Balachandran; Mario A Ostrowski; Alan Cochrane
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

10.  Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev function.

Authors:  Raymond W Wong; Ahalya Balachandran; Matthew Haaland; Peter Stoilov; Alan Cochrane
Journal:  Nucleic Acids Res       Date:  2013-08-13       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.